138 related articles for article (PubMed ID: 38269055)
1. Cancer cell membrane-camouflaged CuPt nanoalloy boosts chemotherapy of cisplatin prodrug to enhance anticancer effect and reverse cisplatin resistance of tumor.
Gan Y; Xie W; Wang M; Wang P; Li Q; Cheng J; Yan M; Xia J; Wu Z; Zhang G
Mater Today Bio; 2024 Feb; 24():100941. PubMed ID: 38269055
[TBL] [Abstract][Full Text] [Related]
2. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
3. Engineering a synergistic antioxidant inhibition nanoplatform to enhance oxidative damage in tumor treatment.
Zhang Q; Sun Z; Sun W; Yu B; Liu J; Jiang C; Lu L
Acta Biomater; 2023 Mar; 158():625-636. PubMed ID: 36608895
[TBL] [Abstract][Full Text] [Related]
4. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
5. A platinum-ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors.
Yang GG; Su XX; Liang BB; Pan ZY; Cao Q; Mao ZW
Chem Sci; 2022 Oct; 13(38):11360-11367. PubMed ID: 36320579
[TBL] [Abstract][Full Text] [Related]
6. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
7. MOF-based nanozyme grafted with cooperative Pt(IV) prodrug for synergistic anticancer therapy.
Wu PH; Cheng PF; Kaveevivitchai W; Chen TH
Colloids Surf B Biointerfaces; 2023 May; 225():113264. PubMed ID: 36921426
[TBL] [Abstract][Full Text] [Related]
8. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
9. Fighting against drug-resistant tumors by the inhibition of γ-glutamyl transferase with supramolecular platinum prodrug nano-assemblies.
Wang L; Liu Z; He S; He S; Wang Y
J Mater Chem B; 2021 Jun; 9(22):4587-4595. PubMed ID: 34059856
[TBL] [Abstract][Full Text] [Related]
10. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
Chen F; Xu G; Tian W; Gou S
Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
[TBL] [Abstract][Full Text] [Related]
11. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
12. Alantolactone-Loaded Pegylated Prodrug Nanocarriers for Synergistic Treatment of Cisplatin-Resistant Ovarian Cancer via Reactivating Mitochondrial Apoptotic Pathway.
Luo Z; Luo Y; Liang X; Lyu Q; Meng F; Chen X; Wang Y; Fang W; Li A; Zhou D
ACS Biomater Sci Eng; 2022 Jun; 8(6):2526-2536. PubMed ID: 35612599
[TBL] [Abstract][Full Text] [Related]
13. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
14. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
15. Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer.
Zhang R; Song X; Liang C; Yi X; Song G; Chao Y; Yang Y; Yang K; Feng L; Liu Z
Biomaterials; 2017 Sep; 138():13-21. PubMed ID: 28550753
[TBL] [Abstract][Full Text] [Related]
16. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
17. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
18. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
19. Hemin-incorporating DNA nanozyme enabling catalytic oxygenation and GSH depletion for enhanced photodynamic therapy and synergistic tumor ferroptosis.
Xiao X; Chen M; Zhang Y; Li L; Peng Y; Li J; Zhou W
J Nanobiotechnology; 2022 Sep; 20(1):410. PubMed ID: 36109814
[TBL] [Abstract][Full Text] [Related]
20. A sulfhydryl blocking reagent BT-4 sensitizes cisplatin-based micelle prodrugs for efficient treatment of breast cancer.
Lin C; Chen Y; Zhu M; Pei J; Zhou Y; Gou M; Ouyang L
Int J Pharm; 2022 Oct; 626():122187. PubMed ID: 36100145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
